|
|
Vaccine Detail
|
ipilimumab, vemurafenib |
| Vaccine Information |
- Vaccine Name: ipilimumab, vemurafenib
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007627
- Type: monoclonal antibody
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Ipilimunab is a CTLA-4 receptor is an intracellular receptor upregulated to the T-cell surface upon T-cell activation. Ipilimunab promptly binds with the CTLA-4 receptor, preventing deactivation of the T-cell response; Vemurafenib is a BRAF V600E kinase inhibitor that halts signal trasnduction, resulting in no phosphorylation of the MAPK pathway and ultimately no survival or proliferation of the cell (Culos and Cuellar, 2013).
|
| References |
Culos and Cuellar, 2013: Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. The Annals of pharmacotherapy. 2013; 47(4); 519-526. [PubMed: 23548648].
|
|
